Infokiri
| Dokumendiregister | Terviseamet |
| Viit | 8-2/25/1071-1 |
| Registreeritud | 10.02.2025 |
| Sünkroonitud | 11.02.2025 |
| Liik | Sissetulev dokument |
| Funktsioon | 8 Nakkushaiguste seire, ennetuse ja tõrje korraldamine |
| Sari | 8-2 Nakkushaiguste epidemioloogiaalane riigiväline kirjavahetus |
| Toimik | 8.1-2/2025 |
| Juurdepääsupiirang | Avalik |
| Juurdepääsupiirang | |
| Adressaat | ECDC respiratory viruses |
| Saabumis/saatmisviis | ECDC respiratory viruses |
| Vastutaja | Kärt Sõber (TA, Peadirektori asetäitja (1) vastutusvaldkond, Nakkushaiguste epidemioloogia osakond) |
| Originaal | Ava uues aknas |
Failid
|
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. |
To: National Focal Points for Viral Respiratory Diseases, National Focal Points for Microbiology
Cc: National Coordinators, Operational Contact Points for COVID-19 and influenza (Microbiology)
Dear colleagues,
We are reaching out regarding a study that RAND Europe is conducting on the preparedness of public health laboratories for respiratory infectious diseases, commissioned and funded by the European Centre for Disease Prevention and Control (ECDC). We are now organising a technical meeting related to that study together with RAND Europe. This study is looking at challenges public health laboratories faced during the COVID-19 pandemic, how they were resolved, how to sustain advances made during the pandemic, and ways to improve long-term preparedness in public health laboratories for future respiratory infections.
As part of this study, RAND Europe and ECDC will be conducting a technical meeting on Tuesday 18th of March from 10am-3pm CET (9am -2pm GMT). This technical meeting is organised to gather further insights from the countries on laboratory preparedness following the survey and interviews that were conducted in December 2024. During the meeting participants will learn about initial findings from this study, based on a literature review and data collection from public health contact points across EU/EEA countries. Participants will be asked to reflect on findings, provide feedback, and discuss views with facilitators and other participants. Topics of discussion will include the effectiveness of different solutions implemented during the pandemic, strategies to sustain advances and measures improve preparedness in public health laboratories.
Two representants per EU/EEA Member State are being invited to partake in the meeting alongside wider public health stakeholders (e.g. from the European Commission, ECDC). The participants could be the people who answered the survey or who were interviewed, or other people among the official contact points (NFPs, NMFP, OCPs). We would be grateful if, as NFP or NMFP, you could evaluate who, among yourselves and the Operational Contact Points for COVID-19 and influenza (Microbiology), would be best suited to represent your country and to contribute to the discussions during this meeting. The meeting will take approximately 5 hours, including a 1-hour lunch break. Due to the limited number of participants we can accommodate, we kindly request that you discuss the topic with colleagues as needed in order to be able to participate in conversation during the day of the event.
More information about the content of the meeting can be find in in the attached Participant Information Sheet. The preliminary agenda is also available for your information at the end of this email. If you have any questions about the meeting or the study, please contact the ECDC or RAND Europe teams.
We are thanking you in advance for taking the time to consider this request. The nominations should be sent to ECDC at [email protected] and cc to RAND Europe (Saoirse Moriarty at [email protected]; Katie Sykes at [email protected]) by 17 February 2025.
Best regards,
The ECDC Respiratory Viruses and Legionella team
and Sarah Parkinson on behalf of RAND Europe
--
Preliminary Agenda of the 18th March’s technical meeting:
|
Time (CET) |
Agenda item |
|
10-10:15 |
Welcome and introductions |
|
10:15-10:45 |
Preliminary findings |
|
10:45-11:10 |
Plenary 1 – Reflections on findings |
|
11:10-12:00 |
Breakout 1 – Challenges and solutions |
|
12:00-1:00 |
Lunch break |
|
1:00-2:00 |
Breakout 2 – Sustaining advances and improving preparedness |
|
2:00-2:10 |
Plenary 2 - Feedback from breakout rooms |
|
2:10-2:50 |
Plenary 3 - Prioritisation of lessons from COVID-19 |
|
2:50-3:00 |
Next steps and close |
|
Confidentiality Notice
If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it and inform its sender of the erroneous transmittal.
You are being invited to take part in a technical meeting as part of research into the challenges that public health laboratories faced during the COVID-19 pandemic and how to make these laboratories more prepared for future public health threats related to respiratory infectious diseases. This meeting is part of a study commissioned by the European Centre for Disease Prevention and Control (ECDC) to RAND Europe. Before you decide to partake in this technical meeting, it is important for you to understand why this study is being done and what it will involve. Please take time to read the following information carefully, and ask us if there is anything that is not clear or if you would like more information.
Study aims
The purpose of this study is to provide evidence to ECDC and key stakeholders in public health around how public health laboratories can be more prepared and resilient in the face of future public health challenges related to respiratory infectious diseases.
The guiding research questions for this study are:
1. What were the main challenges public health laboratories faced during the COVID-19 pandemic?
2. What solutions were implemented by public health laboratories to address these challenges?
3. What were the impacts and implications of the solutions implemented by public health laboratories?
4. What is necessary to sustain the advances made during the COVID-19 pandemic in public health laboratory preparedness?
5. How can the lessons learned during the COVID-19 pandemic be utilised to enhance public health laboratory preparedness for other respiratory infectious diseases and potential new pandemics?
6. What long-term strategies should be developed to ensure public health laboratories remain resilient and adaptable in the face of future public health threats?
Participation details
We have invited you to participate in a technical meeting to inform our understanding of the challenges that public health laboratories faced during the COVID-19 pandemic and how to make these laboratories more prepared for future public health threats related to respiratory infectious disease. We are interested to learn from your professional knowledge and experience as a stakeholder in this field. Your participation in this would be invaluable. If you decide to take part in the technical meeting, a member of the research team will provide further details about the meeting, including a short 2-4 page briefing.
The meeting will be conducted via an online platform (Microsoft Teams) on 18th March 2025, from 10am-3pm CET. It is expected to last 5 hours, including a 1 hour lunch break, and will include a short presentation from the research team, along with small group and plenary discussions.
Before and after the meeting, you will have the chance to provide additional views via an online consultation form. You can respond to this online consultation whether you participate in the technical meeting or not.
Do I have to take part?
No, it is your choice whether to participate or not. You can also withdraw from the project even after you have agreed to take part without giving a reason. You can withdraw up to two weeks after you have participated in the meeting, and there are no consequences for withdrawing. If you do decide to withdraw, your personal data will be destroyed and will not be used in analysis or reporting. As notes will be taken in aggregate, however, it may not be possible to remove all of your individual contributions from our notes. If you do wish to withdraw after the meeting please contact the project manager, whose details are given at the end of this participant information sheet.
Our researchers are happy to discuss any concerns you might have before, during or after the meeting to ensure that you are comfortable with the way that we will use and report the comments you make.
Are there possible disadvantages of taking part?
All information collected from the technical meeting will be reported in aggregate, and no one besides those in the meeting will know what you individually contributed or said during the meeting. We will not use your name or any other information that could be used to identify you in any publications from the study. We will remove any potentially identifiable information, including names of employers, individuals and specific roles within organisations. We will also confirm any direct (anonymous) quotes, should these be used in the report. However, we cannot entirely remove the possibility that readers may identify you, and we cannot guarantee that other participants keep information confidential (although we will request this at the start of the meeting).
What will happen to the results of the study?
We will produce a publicly available report with the results of the study, which will be published by ECDC, and in an academic journal article. We will also publish our findings on the RAND Europe website.
How will the information that I share be kept confidentially?
We will ask your permission to digitally record the meeting. Recording ensures that we capture your comments and perspectives accurately. Detailed notes will be taken of the meeting, and the recording will be referenced as needed. Everything that you say will be treated confidentially and will only be seen by members of the research team, ECDC and other participants of the meeting. We may use things that you have said in the meeting in our reports and other outputs from the evaluation, but we will not use your name or mention any details by which you could be identified.
Data will be held on a secure server. Back-ups taken for disaster recovery purposes will be encrypted and stored in a secure offline site. The data linking your identity to the technical meeting will be stored for one year after completion of the project and then destroyed.
Data protection
All data collection and processing will adhere to GDPR, supported by RAND Europe’s ISO27001 certification. RAND Europe have an in-house team, a dedicated Data Protection Officer, an Ethics Advisory Group and an ISO standards committee to ensure compliance. All discussions and materials from meeting will be treated confidentially. If you would like further information about how the data from this meeting is being used, please contact RAND Europe’s Data Protection officer at [email protected].
Contact for further information
Please contact [email protected] or [email protected] if you have any questions about the study or the technical meeting. If you would like to take part in the meeting, then please respond to the invitation sent by email.
Thank you for considering participating in the technical meeting.
You are being invited to take part in a technical meeting as part of research into the challenges that public health laboratories faced during the COVID-19 pandemic and how to make these laboratories more prepared for future public health threats related to respiratory infectious diseases. This meeting is part of a study commissioned by the European Centre for Disease Prevention and Control (ECDC) to RAND Europe. Before you decide to partake in this technical meeting, it is important for you to understand why this study is being done and what it will involve. Please take time to read the following information carefully, and ask us if there is anything that is not clear or if you would like more information.
Study aims
The purpose of this study is to provide evidence to ECDC and key stakeholders in public health around how public health laboratories can be more prepared and resilient in the face of future public health challenges related to respiratory infectious diseases.
The guiding research questions for this study are:
1. What were the main challenges public health laboratories faced during the COVID-19 pandemic?
2. What solutions were implemented by public health laboratories to address these challenges?
3. What were the impacts and implications of the solutions implemented by public health laboratories?
4. What is necessary to sustain the advances made during the COVID-19 pandemic in public health laboratory preparedness?
5. How can the lessons learned during the COVID-19 pandemic be utilised to enhance public health laboratory preparedness for other respiratory infectious diseases and potential new pandemics?
6. What long-term strategies should be developed to ensure public health laboratories remain resilient and adaptable in the face of future public health threats?
Participation details
We have invited you to participate in a technical meeting to inform our understanding of the challenges that public health laboratories faced during the COVID-19 pandemic and how to make these laboratories more prepared for future public health threats related to respiratory infectious disease. We are interested to learn from your professional knowledge and experience as a stakeholder in this field. Your participation in this would be invaluable. If you decide to take part in the technical meeting, a member of the research team will provide further details about the meeting, including a short 2-4 page briefing.
The meeting will be conducted via an online platform (Microsoft Teams) on 18th March 2025, from 10am-3pm CET. It is expected to last 5 hours, including a 1 hour lunch break, and will include a short presentation from the research team, along with small group and plenary discussions.
Before and after the meeting, you will have the chance to provide additional views via an online consultation form. You can respond to this online consultation whether you participate in the technical meeting or not.
Do I have to take part?
No, it is your choice whether to participate or not. You can also withdraw from the project even after you have agreed to take part without giving a reason. You can withdraw up to two weeks after you have participated in the meeting, and there are no consequences for withdrawing. If you do decide to withdraw, your personal data will be destroyed and will not be used in analysis or reporting. As notes will be taken in aggregate, however, it may not be possible to remove all of your individual contributions from our notes. If you do wish to withdraw after the meeting please contact the project manager, whose details are given at the end of this participant information sheet.
Our researchers are happy to discuss any concerns you might have before, during or after the meeting to ensure that you are comfortable with the way that we will use and report the comments you make.
Are there possible disadvantages of taking part?
All information collected from the technical meeting will be reported in aggregate, and no one besides those in the meeting will know what you individually contributed or said during the meeting. We will not use your name or any other information that could be used to identify you in any publications from the study. We will remove any potentially identifiable information, including names of employers, individuals and specific roles within organisations. We will also confirm any direct (anonymous) quotes, should these be used in the report. However, we cannot entirely remove the possibility that readers may identify you, and we cannot guarantee that other participants keep information confidential (although we will request this at the start of the meeting).
What will happen to the results of the study?
We will produce a publicly available report with the results of the study, which will be published by ECDC, and in an academic journal article. We will also publish our findings on the RAND Europe website.
How will the information that I share be kept confidentially?
We will ask your permission to digitally record the meeting. Recording ensures that we capture your comments and perspectives accurately. Detailed notes will be taken of the meeting, and the recording will be referenced as needed. Everything that you say will be treated confidentially and will only be seen by members of the research team, ECDC and other participants of the meeting. We may use things that you have said in the meeting in our reports and other outputs from the evaluation, but we will not use your name or mention any details by which you could be identified.
Data will be held on a secure server. Back-ups taken for disaster recovery purposes will be encrypted and stored in a secure offline site. The data linking your identity to the technical meeting will be stored for one year after completion of the project and then destroyed.
Data protection
All data collection and processing will adhere to GDPR, supported by RAND Europe’s ISO27001 certification. RAND Europe have an in-house team, a dedicated Data Protection Officer, an Ethics Advisory Group and an ISO standards committee to ensure compliance. All discussions and materials from meeting will be treated confidentially. If you would like further information about how the data from this meeting is being used, please contact RAND Europe’s Data Protection officer at [email protected].
Contact for further information
Please contact [email protected] or [email protected] if you have any questions about the study or the technical meeting. If you would like to take part in the meeting, then please respond to the invitation sent by email.
Thank you for considering participating in the technical meeting.